China’s Innovent Biologics secures over $300 million investment from Sanofi
The all-cash investment by Sanofi unit Sanofi Foreign Participations BV will be at a price of $42.42 per Innovent share, representing a premium of about 29 per cent to the stock's last close
Innovent Biologics said recently Paris-based Sanofi would invest $2.42 billion ($307.88 million) in the biopharma group to jointly develop two cancer drugs in China.
The all-cash investment by Sanofi unit Sanofi Foreign Participations BV will be at a price of $42.42 per Innovent share, representing a premium of about 29 per cent to the stock’s last close.
Innovent said it had also entered into a licence agreement with Sanofi Foreign Participations for the commercialisation of the two oncology medicines.
The Jiangsu, China-based company said SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head and neck tumours, among others.
Sanofi will receive up to 140 million Euros ($143.44 million) in milestone payments and royalties on net sales of the two drugs in China upon new drug application approvals, Innovent said.
Edits by EP News Bureau
- Advertisement -
Thanks for sharing such an informative piece of content.
Great article here , Good article.